Artecel, Inc.
Records under this name other than patents Artecel, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,249,393 | Adipose Derived Adult Stem Cells in Hepatic Regeneration Formerly held Lapsed on the fee record Ended Feb 2, 2024 · High confidence | Lapsed on the fee record | Ended Feb 2, 2024 | High confidence |
| US 6,555,374 | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof Formerly held Term ended Term ended Dec 10, 2020 · From the USPTO record | Term ended | Term ended Dec 10, 2020 | From the USPTO record |
| US 6,242,200 | Screening for SUR1 antagonists using adipocytes Formerly held Term ended Term ended Jun 12, 2020 · From the USPTO record | Term ended | Term ended Jun 12, 2020 | From the USPTO record |
| US 6,391,297 | Differentiation of adipose stromal cells into osteoblasts and uses thereof Formerly held Term ended Term ended May 19, 2020 · From the USPTO record | Term ended | Term ended May 19, 2020 | From the USPTO record |
| US 6,429,013 | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair Formerly held Term ended Term ended May 17, 2020 · From the USPTO record | Term ended | Term ended May 17, 2020 | From the USPTO record |
| US 9,255,249 | Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates Formerly held Lapsed on the fee record Ended Feb 9, 2020 · From the USPTO record | Lapsed on the fee record | Ended Feb 9, 2020 | From the USPTO record |
| US 9,200,255 | Differentiation of adipose stromal cells into osteoblasts and treating bones Formerly held Lapsed on the fee record Ended Dec 1, 2019 · From the USPTO record | Lapsed on the fee record | Ended Dec 1, 2019 | From the USPTO record |
| US 8,048,673 | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair Formerly held Lapsed on the fee record Ended Nov 1, 2019 · From the USPTO record | Lapsed on the fee record | Ended Nov 1, 2019 | From the USPTO record |
| US 6,100,047 | Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes Formerly held Term ended Term ended Apr 7, 2019 · From the USPTO record | Term ended | Term ended Apr 7, 2019 | From the USPTO record |
| US 6,492,130 | Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes Formerly held Term ended Ended no later than Apr 7, 2019 · From the USPTO record | Term ended | Ended no later than Apr 7, 2019 | From the USPTO record |